August 22, 2024 | 11:00AM EST | 3:00PM UTC In this webinar, you will: Explore how using a proteomics approach with REpAb® de novo sequencing accesses a larger diversity of antibodies, and enhances antibody discovery workflows. Case study on de novo sequencing functional and neutralizing antibodies directly from the serum of a Human [...]
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
Written by: Genya Gorshtein, MSc Published: June 10, 2024 Contents Introduction Alanine Scanning Mutagenesis Epitope Mapping HDX-MS Epitope Mapping Antibody Epitope Mapping Services Introduction Epitope mapping elucidates the antibody function by identifying specific binding sites on the antigen that interact with the antibody. Alanine [...]
In this webinar, you will learn: How AI and HDX-MS are applied in screening, epitope mapping, and selecting neutralizing antibodies against SARS-Cov-2. The predictive capabilities of AI computational modeling and its validation and refinement by high-resolution HDX-MS. How the integration of AI with HDX-MS informs antibody characterization for the accelerated development of therapeutic [...]
Written by: Genya Gorshtein, MSc Published: May 29, 2024 Contents Introduction What is Epitope Binning Value of Epitope Binning in Early Discovery Stages Epitope Binning with SPR on Biacore 1K Introduction An epitope is an inherent property of an antibody that cannot be altered [...]
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
A Canadian Multiple Myeloma (MM) clinical trial sponsored by Rapid Novor, has enrolled its first patient. This is the first Canadian prospective clinical study aiming to evaluate the EasyM™ assay (mass spectrometry measurement of a myeloma biomarker) for disease response in newly diagnosed MM patients (NDMM) receiving standard of care treatment. A clinical [...]
In this webinar, you will… Learn the details of LC-MS based antibody characterization in early discovery and production pipelines Explore in-depth the analytical methodologies and strategies essential for comprehensive antibody characterization, covering post-translational modifications, glycan profiles, peptide mapping, and disulfide linkages Ask your burning questions and get expert guidance on navigating antibody [...]
Written by: Genya Gorshtein, MSc Published: April 19, 2024 Contents Introduction Bispecifics and Multispecific Antibody Formats Mechanism of Action of Bispecific Antibodies Bispecific and Multispecific Development with Rapid Novor Introduction The complex nature of diseases often limits the therapeutic efficacy of monovalent antibodies. To [...]
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
Written by: Genya Gorshtein, MSc Published: April 3, 2024 Contents Introduction Membrane Proteins are Difficult Antigens Strategies for Utilizing Membrane Proteins as Antigens in Antibody Discovery In Vivo Antibody Discovery Using Mass Spectrometry Introduction Membrane proteins orchestrate a wide range of cellular functions, such [...]
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
Rapid Novor Inc and MAbSilico announced that they have partnered to provide the world’s first AI-driven HDX-MS epitope mapping service for antibody development. By seamlessly integrating experimental data from HDX-MS with predictive analytics derived from AI-driven computational modeling, researchers can gain a comprehensive understanding of antibody structure, dynamics, and interactions with unparalleled precision and [...]
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
Written by: Genya Gorshtein, MSc Published: January 8, 2024 Contents Introduction Glycoengineering of Therapeutic mAbs Glycoengineering Methods Informed Glycan Engineering through LC-MS Glycan Analysis Introduction Glycosylation plays a crucial role in antibody functions, influencing protein folding, trafficking, stability, and half-life. While the glycosylated residue [...]
Written by: Jenna Kerry, MSc Published: October 25, 2024 Published: October 25, 2023 Contents Introduction What is Affinity Maturation? How Does Somatic Hypermutation Work? Applications of Affinity Maturation De Novo Proteomic Sequencing of Antibodies Introduction The immune system is a complex system responsible for [...]
Written by: Genya Gorshtein, MSc Published: October 18, 2023 Contents Introduction Types of Glycans How are Proteins Glycosylated? Why are Proteins Glycosylated? Protein Glycosylation in the Immune System Importance of Understanding Glycan Profiles of Proteins Discover Glycan Sites and Profiles with Rapid Novor Introduction [...]
In this webinar, you will learn: Workflows for antibody characterization that extend beyond the primary amino acid sequence How to leverage HDX-MS for epitope mapping and SPR for binding kinetics to understand the mechanism of action and maximize the effectiveness of your characterization efforts How to ensure high-quality antibody production with [...]
Written by: Genya Gorshtein, MSc Published: September 12, 2023 Contents Introduction Mechanisms That Influence Protein Aggregation and Stability Sequence and Structural Characteristics That Impact Antibody Aggregation and Stability Engineered Antibody Formats Influence Protein Aggregation Strategies to Reduce Antibody Aggregation Propensity Improving Antibody Developability with Next Generation Protein Sequencing and Proteomics [...]
Our client is a biotechnology company developing therapeutics that target cancer-specific carbohydrate antigens on the surface of tumour cells.
Our client is a biotechnology company developing therapeutics that target cancer-specific carbohydrate antigens on the surface of tumour cells.
Written by: Genya Gorshtein, MSc Published: June 13, 2023 Contents Introduction How do Primary and Secondary Antibodies Work? How are Primary and Secondary Antibodies Generated? Selecting Primary and Secondary Antibodies for Immunoassays Developing Reliable Reagents for Immunoassays with Rapid Novor Introduction Immunoassays have a [...]
Written by: Genya Gorshtein, MSc Published: May 9, 2023 Contents Introduction Hybridoma Instability Leads to mAb Irreproducibility Batch-to-Batch Variation in Polyclonal Antibodies Antibody Sequencing and Recombinant Expression Ensures Reproducible Antibody Reagents Generating Reproducible Reagents with Rapid Novor Introduction Antibodies (Abs) are indispensable tools in [...]
Written by: Genya Gorshtein, MSc Published: April 21, 2023 Contents Introduction Target Specification for First Generation Antibodies Patent Strategies for Second-Generation Antibodies Next Generation Protein Sequencing and Proteomics Strengthens IP Protections Introduction Intellectual property (IP) protection is a critical step during the commercialization of antibodies [...]
Written by: Genya Gorshtein, MSc Published: February 17, 2023 Contents The Drug Development Pathway Target Discovery and Validation Antibody Discovery Characterization and Lead Selection Engineering and Optimization Candidate Selection Therapeutic Antibody Discovery with Rapid Novor The Drug Development Pathway The four phases in the drug [...]
Written by: Genya Gorshtein, MSc Published: January 6, 2023 Contents Introduction What is Affinity? What is Avidity? Measuring Affinity and Avidity: ELISA or SPR? Measuring Affinity And Avidity For Biological Applications Affinity and Avidity Analysis via SPR with Rapid Novor Introduction Kinetics of antibody-antigen interactions [...]
Written by: Genya Gorshtein, MSc Published: November 1, 2022 Contents Introduction Approaches for Engineering Antibody Therapeutics Driving Antibody Engineering with Next Generation Protein Sequencing and Proteomics Introduction Antibody engineering encompasses various development, production strategies, and modification techniques to improve the biological properties of monoclonal antibodies (mAbs) [...]
Written by: Genya Gorshtein, MSc Published: November 25, 2022 Contents Introduction General PROTAC Structure and Function Antibody-Conjugated PROTACs Developing AbPROTACs with De Novo Antibody Sequencing and Proteomics Introduction Small-molecule drug development is aimed at inhibiting disease-promoting protein function through occupancy-driven protein inhibition. A major caveat of [...]
Written by: Genya Gorshtein, MSc Published: September 14, 2022 Contents Introduction ADCs as Novel Anti-Cancer Chemotherapeutics Key Components of ADCs Future Generation of ADCs De Novo Protein Sequencing Applications in ADC Development Introduction An antibody-drug conjugate (ADC) is a monoclonal antibody (mAb) with a covalently attached [...]
Written by Genya Gorshtein, MSc Updated: January 27, 2023 (Published: August 31, 2022) Contents How is Antibody Diversity Generated? Which Steps Contribute to the Generation of Antibody Diversity? Antibody Loci and V(D)J Recombination Somatic Hypermutation Class Switch Recombination De Novo Proteomic Sequencing of Antibodies How is Antibody [...]
Written by: Genya Gorshtein, MSc Published: August 18, 2022 Contents Introduction How are Polyclonal Antibodies Produced? Applications of Polyclonal Antibodies Challenges of Polyclonal Antibodies De Novo Polyclonal Antibody Sequencing Introduction Polyclonal antibodies (pAbs) are a heterogeneous mix of antibodies derived from B cells in the [...]
Written by Genya Gorshtein, MSc August 10, 2022 Contents General Structure of Antibodies Fab and Fc Fragments Hinge Region CDR and FR Regions Antibody Structure Analysis Services General Structure of Antibodies Antibodies or immunoglobulins (Ig) maintain a common quaternary structure consisting of two identical heavy chains (HCs) and [...]